LobbyingData.com Logo

Amneal Pharmaceuticals (AMRX) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.


Discover Amneal Pharmaceuticals’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.


Using our intelligently designed and intuitive dataset, you can quickly understand how Amneal Pharmaceuticals (AMRX) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Amneal Pharmaceuticals (AMRX) lobbying for?

Summary of Lobbying Data:

Amneal Pharmaceuticals hired three lobbying firms, namely Michael Best Strategies Llc, Fierce Government Relations, Inc., and Mehlman Castagnetti Rosen & Thomas, to lobby on general issues related to manufacturing, pharmacy, and health issues. They lobbied specifically on issues related to pandemic preparedness, supply chain, monitoring legislative and regulatory efforts related to domestic supply chains of generic drugs, onshoring essential antibiotics act, H.R. 5376-build back better act, and generic drug issues. Amneal Pharmaceuticals lobbied government agencies such as the White House Office, House of Representatives, Food & Drug Administration (FDA), Department of Health & Human Services (HHS), and Senate.

One could infer that Amneal Pharmaceuticals is lobbying on these specific issues to protect and promote their interests in the pharmaceutical industry. The COVID-19 pandemic has brought global attention to the importance of pandemic preparedness and supply chain, which may have motivated Amneal Pharmaceuticals to focus their lobbying efforts in these areas. The company may also be working to ensure favorable policies and regulations related to domestic manufacturing and supply of generic drugs, which could impact their business operations. Additionally, onshoring essential antibiotics act could lead to changes in the pharmaceutical supply chain, which could also impact the company’s operations.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore